Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Patients must have a diagnosis of chronic GVHD with fibrotic/scleroderma-like features. This diagnosis can be made clinically or by histopathology.~* Patients must have active disease with at least one of the following manifestations: skin sclerosis, symptomatic bronchiolitis obliterans, extensive lung fibrosis, pathologically demonstrated visceral fibrotic involvement of the gut.~* Patients with corticosteroid refractory or dependant cGVHD are eligible. Steroid-refractory chronic GVHD is defined as chronic GVHD of sustained severity during the last full month during which the patients received the equivalent of prednisone 0.5 mg/kg or more per day or 1 mg/kg or more every other day.~* Age under 21 years old~Exclusion criteria~* Patients who have had chemotherapy, radiotherapy within 4 weeks prior to entering the study.~* Patients who have not recovered from adverse events.~* Prior treatment with imatinib mesylate or other tyrosine kinase inhibitor after the date of transplant.~* Patients on pregnancy or lactating

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate, Mycophenolate mofetil (Type: EXPERIMENTAL): MMF 15-20mg/kg (Max 1 g) bid + Imatinib mesylate qd~* Dose of imatinib : starting dose 260 mg/m2/d (Max. 400 mg)~* Imatinib dose adjustment : Dose is adjusted according to the guidelines if there is serious adverse event, toxicity, or intolerance.

Based on this trial design, predict the completion outcome and termination type (if applicable).